Recent Lassa fever outbreaks in Africa show vital need for new products that can be processed in any clinical or field lab
DENVER and NEW ORLEANS, May 7 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced an extension of the collaborative effort for developing test kits for the detection of viral hemorrhagic fever (VHF).
The National Institutes of Health (NIH) has awarded a five-year grant to Tulane University for further development of the VHF kits. Collaborating with Corgenix and Tulane in this grant are Autoimmune Technologies, LLC, Vybion, Inc. and various partners in West Africa.
"We are extremely pleased to be part of this collaboration and to have received the NIH grant," said Douglass Simpson, Corgenix President and CEO. "We have made major strides in the development and clinical study phases and this will enable us to further develop the assays, complete the clinical studies and achieve full commercialization."
This is the second grant awarded to Tulane for Lassa virus products. Under the original grant awarded in 2005, the group developed and patented new recombinant proteins for Lassa virus and developed several viral detection products which were deployed in Africa for clinical testing. Under the new grant, Corgenix and the other partners will move the prototype Lassa products into full commercialization. Current tests typically require the culture of live Lassa virus in a high-containment laboratory to produce reagents. These tests are expensive, laborious to produce, and not commercially available, leaving no adequate options for laboratory diagnosis of VHFs in sub-Saharan Africa where most VHFs are endemic.
Joseph Fair, Ph.D., MPH, Director, Global Field Operations, Global Viral Forecasting Initiative, San Franci
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Corgenix Medical Corporation|
Copyright©2009 PR Newswire.
All rights reserved
. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2
. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer3
. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain4
. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer5
. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia6
. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,9477
. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results8
. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice9
. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results10
. Amicus Therapeutics Announces Second Quarter 2007 Financial Results11
. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights